Main

related bits

0

processing priority

4

site type

0 (generic, awaiting analysis)

review version

11

html import

20 (imported)

Events

first seen date

2024-03-15 03:35:33

expired found date

-

created at

2024-07-06 09:56:25

updated at

2025-06-05 10:27:50

Domain name statistics

length

20

crc

64157

tld

2211

nm parts

0

nm random digits

0

nm rare letters

0

Connections

is subdomain of id

-

previous id

0

replaced with id

0

related id

-

dns primary id

173561409

dns alternative id

0

lifecycle status

0 (unclassified, or currently active)

Subdomains and pages

deleted subdomains

0

page imported products

0

page imported random

0

page imported parking

0

Error counters

count skipped due to recent timeouts on the same server IP

0

count content received but rejected due to 11-799

0

count dns errors

0

count cert errors

0

count timeouts

1

count http 429

0

count http 404

0

count http 403

0

count http 5xx

0

next operation date

2025-03-28 21:51:16

Server

server bits

server ip

-

Mainpage statistics

mp import status

20

mp rejected date

-

mp saved date

-

mp size orig

76736

mp size raw text

1720

mp inner links count

6

mp inner links status

10 (links queued, awaiting import)

Open Graph

title

DICE THERAPEUTICS

description

DICE brings together industry veterans with a passion for immunology and small molecule discovery. We envision a world where convenient oral medicines with biologic-like efficacy are available to pati

site name

DICE THERAPEUTICS

author

updated

2026-03-08 14:47:49

raw text

DICE THERAPEUTICS Skip to main content About Approach Pipeline Patients Careers Press Release Developing transformative medicines for autoimmune and inflammatory diseases Expecting More Out of Medicine We design and develop innovative oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. We are developing a growing pipeline of high-impact oral therapeutic candidates. Our lead program targets the IL-17 cytokine for psoriasis and other IL-17 mediated diseases. Our Pipeline DELSCAPE: A New Approach to Immunology Currently available biologics have transformed the inflammatory disease landscape by targeting protein-protein interactions (PPIs) such as the binding of an inflammatory cytokine to its receptor. However, these medicines are not ideally suited for chronic treatment and face multiple challenges, including administration through injections or intravenous infusions and regula...

Text analysis

redirect type

0 (-)

block type

0 (no issues)

detected language

1 (English)

category id

Medycyna (36)

index version

1

spam phrases

0

Text statistics

text nonlatin

0

text cyrillic

0

text characters

1393

text words

228

text unique words

140

text lines

35

text sentences

9

text paragraphs

4

text words per sentence

25

text matched phrases

0

text matched dictionaries

0

RSS

rss status

32 (unknown)

rss found date

2024-03-16 01:25:56

rss size orig

54350

rss items

20

rss spam phrases

0

rss detected language

1 (English)

inbefore feed id

-

inbefore status

0 (new)

Sitemap

sitemap status

34 (reserved: import paused pending content quality/relevance assessment after importing first 500 pages)

sitemap review version

2

sitemap urls count

55

sitemap urls adult

0

sitemap filtered products

0

sitemap filtered videos

0

sitemap found date

2024-03-15 03:35:33

sitemap process date

2025-04-01 16:31:34

sitemap first import date

-

sitemap last import date

2025-06-05 10:27:50